Fluidigm to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Fluidigm Corporation (Nasdaq:FLDM) announces participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1-2, 2020. A pre-recorded fireside chat with President and CEO Chris Linthwaite will be available on November 24 at 10:00 am ET, discussing the company's business strategy and financial performance. The recording will be accessible on their investor website. Fluidigm specializes in translational and clinical research, focusing on cancer and immunology, providing multi-omic solutions to improve health insights.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, and Wednesday, December 2.
In advance of the virtual conference and investor meetings, a pre-recorded fireside chat with Chris Linthwaite, President and CEO, will be made available, Tuesday, November 24, at 10:00 am ET. During the fireside chat, the company will present updates regarding Fluidigm’s business strategy and financial performance.
The recording of the company’s fireside chat will be available in the Events & Presentations section of the company’s investor website.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, Advanta and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Contact:
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com
FAQ
What is Fluidigm's participation in the Piper Sandler Virtual Healthcare Conference?
When will Fluidigm's fireside chat be available for viewing?
What topics will be covered in Fluidigm's fireside chat?
Where can I find the recording of Fluidigm's fireside chat?
What does Fluidigm focus on in its research?
